NAS:SGEN (USA) Also trade in: Germany

Seattle Genetics Inc

$ 76.29 -2.07 (-2.64%)
Volume: 495,596 Avg Vol (1m): 1,123,454
Market Cap $: 12.34 Bil Enterprise Value $: 12.04 Bil
P/E (TTM): 0.00 P/B: 9.61
Earnings Power Value -9.2
Net Current Asset Value 2.35
Tangible Book 4.35
Projected FCF -2.49
Median P/S Value 82.71
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 4.74
Cash-To-Debt range over the past 10 years
Min: 4.74, Med: 10000, Max: 10000
Current: 4.74
4.74
10000
Equity-to-Asset 0.81
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.77, Max: 0.96
Current: 0.81
0.36
0.96
Debt-to-Equity 0.06
Debt-to-Equity range over the past 10 years
Min: 0.05, Med: 0.06, Max: 0.06
Current: 0.06
0.05
0.06
Debt-to-EBITDA -0.40
Debt-to-EBITDA range over the past 10 years
Min: -0.4, Med: 0, Max: 0
Current: -0.4
-0.4
0
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 23.95
DISTRESS
GREY
SAFE
Beneish M-Score -2.68
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -24.61%
WACC 12.08%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -30.13
Operating Margin range over the past 10 years
Min: -163.3, Med: -37.81, Max: -23.35
Current: -30.13
-163.3
-23.35
Net Margin % -36.94
Net Margin range over the past 10 years
Min: -160.41, Med: -33.76, Max: -23.22
Current: -36.94
-160.41
-23.22
ROE % -21.18
ROE range over the past 10 years
Min: -79.94, Med: -27.14, Max: -19.14
Current: -21.18
-79.94
-19.14
ROA % -17.91
ROA range over the past 10 years
Min: -40.26, Med: -16.99, Max: -12
Current: -17.91
-40.26
-12
ROC (Joel Greenblatt) % -116.93
ROC (Joel Greenblatt) range over the past 10 years
Min: -903.49, Med: -253.26, Max: -116.93
Current: -116.93
-903.49
-116.93
3-Year Total Revenue Growth Rate 24.80
3-Year Revenue Growth Rate range over the past 10 years
Min: 7.7, Med: 28.65, Max: 148.1
Current: 16.8
7.7
148.1
3-Year Total EBITDA Growth Rate -30.00
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.6, Med: -4.25, Max: 30.1
Current: -21.7
-31.6
30.1
3-Year EPS w/o NRI Growth Rate -14.90
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -27.9, Med: -3.6, Max: 34
Current: -14.9
-27.9
34

Ratios

Current vs industry vs history
PB Ratio 9.61
PB Ratio range over the past 10 years
Min: 3.61, Med: 9.7, Max: 35.62
Current: 9.61
3.61
35.62
PS Ratio 16.16
PS Ratio range over the past 10 years
Min: 10.06, Med: 17.52, Max: 45.33
Current: 16.16
10.06
45.33
EV-to-EBIT -52.76
EV-to-EBIT range over the past 10 years
Min: -102.6, Med: -39.5, Max: -4.7
Current: -52.76
-102.6
-4.7
EV-to-EBITDA -59.97
EV-to-EBITDA range over the past 10 years
Min: -120.2, Med: -44.7, Max: -4.9
Current: -59.97
-120.2
-4.9
EV-to-Revenue 15.89
EV-to-Revenue range over the past 10 years
Min: 7.4, Med: 16, Max: 40.4
Current: 15.89
7.4
40.4
Current Ratio 3.03
Current Ratio range over the past 10 years
Min: 2.65, Med: 4.92, Max: 30.03
Current: 3.03
2.65
30.03
Quick Ratio 2.70
Quick Ratio range over the past 10 years
Min: 2.29, Med: 4.56, Max: 30.03
Current: 2.7
2.29
30.03
Days Inventory 333.11
Days Inventory range over the past 10 years
Min: 234.02, Med: 514.46, Max: 639.76
Current: 333.11
234.02
639.76
Days Sales Outstanding 87.81
Days Sales Outstanding range over the past 10 years
Min: 40, Med: 61.03, Max: 562.77
Current: 87.81
40
562.77
Days Payable 180.79
Days Payable range over the past 10 years
Min: 180.79, Med: 224.03, Max: 1833.79
Current: 180.79
180.79
1833.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -8.20
3-Year Share Buyback Rate range over the past 10 years
Min: -23.5, Med: -11, Max: -1.7
Current: -8.2
-23.5
-1.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 17.54
Price-to-Tangible-Book range over the past 10 years
Min: 1.78, Med: 7.96, Max: 33.4
Current: 17.54
1.78
33.4
Price-to-Median-PS-Value 0.93
Price-to-Median-PS-Value range over the past 10 years
Min: 0.59, Med: 1.16, Max: 100
Current: 0.93
0.59
100
Earnings Yield (Joel Greenblatt) % -1.90
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.4, Med: -2.5, Max: -1
Current: -1.9
-21.4
-1

» SGEN's 30-Y Financials

Financials (Next Earnings Date: 2019-10-25)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SGEN

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare OCSE:GMAB NAS:SRPT HKSE:02269 OCSE:NZYM B NAS:ARRY XAMS:GLPG NAS:BMRN XBRU:UCB NAS:IONS HKSE:01177 XKRX:207940 NAS:SAGE NAS:ALNY NAS:TECH NAS:NBIX NAS:JAZZ NAS:BLUE HKSE:06160 NAS:INCY TSE:4587
Traded in other countries SGT.Germany
Address 21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

More Statistics

Revenue (TTM) (Mil) $ 757.58
EPS (TTM) $ -1.74
Beta 1.76
Volatility % 51.6
52-Week Range $ 50.71 - 84.37
Shares Outstanding (Mil) 161.72

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N